Take a new combination medication for advanced ovarian cancer

Take a new combination medication for advanced ovarian cancer | stella

What is this trial?

This trial is testing Distamab Vedotin combined with carboplatin chemotherapy as a first-line (initial) treatment for advanced ovarian cancer. The study focuses on patients whose cancer cells have high levels of a protein called HER2. Researchers hope this new combination will be effective while causing fewer side effects than the standard chemotherapy currently used.

Standard ovarian cancer chemotherapy has been used for years, but it can cause serious side effects like nerve damage, kidney injury, and allergic reactions. This medication is a newer type of targeted drug that may work better for cancers with HER2 protein overexpression and might be gentler on patients' bodies.

Do you qualify?

You likely qualify if…

you have been diagnosed with stage II–IV ovarian, fallopian tube, or peritoneal cancer that has been confirmed by a pathologist
you have already had surgery to remove as much cancer as possible (debulking surgery) before joining the study
your cancer cells have high levels of HER2 protein (shown as 2+ or 3+ on a test called immunohistochemistry)
you have never received chemotherapy before
your overall health is good enough to tolerate treatment (ECOG score of 2 or lower)
your heart, liver, kidneys, and blood counts are in acceptable ranges

You likely don't qualify if…

you have received other cancer treatments like radiation or immunotherapy within the past month
you have brain metastases (cancer spread to the brain) or central nervous system disease
you have had moderate or severe nerve damage (peripheral neuropathy grade 2 or higher) from any cause
you have serious uncontrolled medical conditions like severe heart disease, uncontrolled diabetes, or active infections
you have a history of another cancer within the past 5 years (except skin cancer or cervical cancer that has been cured)

What participation looks like

You would receive the new medication and carboplatin chemotherapy together by infusion on day 1, with treatments repeating every 3 weeks for a maximum of 6 cycles (about 4 to 5 months total). This involves regular visits to the study center for infusions and monitoring, including blood tests and scans to check how well the treatment is working and track any side effects.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

New combination treatment for advanced ovarian cancer after surgery

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)